← Back to Search

Alpha-1 Adrenergic Receptor Antagonist

Terazosin for Healthy Subjects

Phase 1
Waitlist Available
Led By Jordan Schultz, PharmD
Research Sponsored by University of Iowa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Healthy Men or women aged 60-90
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up ongoing (days 1 - 37)
Awards & highlights

Study Summary

This trial will help researchers understand if Terazosin helps to reduce symptoms related to certain medical conditions.

Who is the study for?
This trial is for healthy men and women aged between 60-90 years old. The details about what might exclude someone from participating are not provided, but typically would involve factors that could affect the safety of participants or the results of the study.Check my eligibility
What is being tested?
The study is testing Terazosin (TZ) in a small group of 6 healthy adults to see how well it engages with its target in the body. Participants will undergo advanced imaging tests like PET/CT scans and high-field MRI, along with blood tests, and may choose to have a spinal tap procedure.See study design
What are the potential side effects?
Since this trial involves healthy subjects, side effects might include reactions at injection sites, discomfort from imaging procedures or blood draws, headache or back pain after lumbar puncture if chosen.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~ongoing (days 1 - 37)
This trial's timeline: 3 weeks for screening, Varies for treatment, and ongoing (days 1 - 37) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in ATP in the blood from baseline to 1 week (1mg of terazosin)
Change in ATP in the blood from baseline to 5 week (1mg of terazosin)
Change in ATP in the brain from baseline to 1 week (1mg of terazosin)
+7 more
Secondary outcome measures
Safety and Tolerability

Trial Design

1Treatment groups
Experimental Treatment
Group I: Primary CohortExperimental Treatment1 Intervention
Titrating doses of terazosin starting at 1mg daily and increasing to 5mg daily on a weekly basis for five weeks.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of IowaLead Sponsor
446 Previous Clinical Trials
879,484 Total Patients Enrolled
Michael J. Fox Foundation for Parkinson's ResearchOTHER
112 Previous Clinical Trials
535,138 Total Patients Enrolled
Jordan Schultz, PharmDPrincipal Investigator - University of Iowa
University of Iowa
1 Previous Clinical Trials
13 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Nature Chemical BiologyJournal
Terazosin Activates Pgk1 and Hsp90 to Promote Stress Resistance
Chen, Xinping, Chunyue Zhao, Xiaolong Li, Tao Wang, Yizhou Li, Cheng Cao, Yuehe Ding, et al.. 2014. “Terazosin Activates Pgk1 and Hsp90 to Promote Stress Resistance”. Nature Chemical Biology. Springer Science and Business Media LLC. doi:10.1038/nchembio.1657.
The Lancet NeurologyJournal
Mitochondria in the Aetiology and Pathogenesis of Parkinson's Disease
Schapira, Anthony HV. 2008. “Mitochondria in the Aetiology and Pathogenesis of Parkinson's Disease”. The Lancet Neurology. Elsevier BV. doi:10.1016/s1474-4422(07)70327-7.
NutritionJournal
Brain Fuel Metabolism, Aging, and Alzheimer’s Disease
Cunnane, Stephen, Scott Nugent, Maggie Roy, Alexandre Courchesne-Loyer, Etienne Croteau, Sébastien Tremblay, Alex Castellano, et al.. 2011. “Brain Fuel Metabolism, Aging, and Alzheimer’s Disease”. Nutrition. Elsevier BV. doi:10.1016/j.nut.2010.07.021.
Journal of Biomedicine and BiotechnologyJournal
Classic and New Animal Models of Parkinson's Disease
Blesa, Javier, Sudarshan Phani, Vernice Jackson-Lewis, and Serge Przedborski. 2012. “Classic and New Animal Models of Parkinson's Disease”. Journal of Biomedicine and Biotechnology. Hindawi Limited. doi:10.1155/2012/845618.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top